Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Linjuan Zeng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8357-1858; OpenAlex author ID A5049295143. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
27
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 3 papers

Papers 19

  1. TSPAN7 inhibits pancreatic cancer progression by suppressing DNA double-strand break repair and enhances sensitivity to immunochemotherapy. Last author DOI 10.1016/j.bcp.2025.117199↗
  2. Single-cell transcriptome analysis identifies MIF as a novel tumor-associated neutrophil marker for pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41698-025-01085-3↗
  3. Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. Co-author DOI 10.1039/d5nr90172c↗
  4. GDNF-induced phosphorylation of MUC21 promotes pancreatic cancer perineural invasion and metastasis by activating RAC2 GTPase. Last author DOI 10.1038/s41388-024-03102-4↗
  5. Molecular Classification of Genes Associated with Hypoxic Lipid Metabolism in Pancreatic Cancer. Last author DOI 10.3390/biom12101533↗
  6. S100A10 Promotes Pancreatic Ductal Adenocarcinoma Cells Proliferation, Migration and Adhesion through JNK/LAMB3-LAMC2 Axis. Last author DOI 10.3390/cancers15010202↗
  7. S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemc… Last author DOI 10.1016/j.bcp.2020.114396↗
  8. A new 7-gene survival score assay for pancreatic cancer patient prognosis prediction. Last author PMID 33575083↗
  9. Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. Co-author DOI 10.1039/c9nr04976b↗
  10. MicroRNA hsa-miR-623 directly suppresses MMP1 and attenuates IL-8-induced metastasis in pancreatic cancer. Last author DOI 10.3892/ijo.2019.4803↗
  11. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8. Co-author DOI 10.1002/cam4.1824↗
  12. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. Co-author DOI 10.1002/ijc.31248↗
  13. MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells. Last author DOI 10.7150/thno.24281↗
  14. New developments in the early diagnosis of pancreatic cancer. Co-author DOI 10.1080/17474124.2017.1271323↗
  15. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. Last author DOI 10.1111/cas.13267↗
  16. Pancreatic Cancer Epidemiology, Detection, and Management. First author DOI 10.1155/2016/8962321↗
  17. A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy. Co-author DOI 10.1166/jbn.2016.2269↗
  18. Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in China. Co-author DOI 10.3747/co.22.2150↗
  19. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic can… Co-author DOI 10.1016/j.nano.2013.08.007↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yinting Chen · 11 shared papers, 2014–2025 · strength 0.99
  2. Kaihong Huang · 11 shared papers, 2014–2025 · strength 0.94
  3. Guoda Lian · 9 shared papers, 2016–2025 · strength 0.85
  4. Yaning Li · 4 shared papers, 2022–2025 · strength 0.83
  5. Yaqing Li · 7 shared papers, 2016–2025 · strength 0.72
  6. Yan Zeng · 3 shared papers, 2024–2025 · strength 0.67
  7. Lisi Luo · 4 shared papers, 2021–2025 · strength 0.64
  8. Chumei Huang · 7 shared papers, 2017–2021 · strength 0.63
  9. Jiajia Li · 3 shared papers, 2016–2025 · strength 0.40
  10. Jinmao Zou · 2 shared papers, 2020–2025 · strength 0.37
  11. Shangxiang Chen · 2 shared papers, 2020–2025 · strength 0.37
  12. Kege Yang · 5 shared papers, 2016–2018 · strength 0.35
  13. Shaojie Chen · 5 shared papers, 2016–2018 · strength 0.35
  14. Hai Lin · 2 shared papers, 2022–2024 · strength 0.32
  15. Yutong Chen · 2 shared papers, 2019–2022 · strength 0.26
  16. Shaojie Chen · 1 shared paper, 2025 · strength 0.26
  17. Qiubo Zhang · 4 shared papers, 2014–2018 · strength 0.25
  18. Hai Lin · 1 shared paper, 2025 · strength 0.23
  19. Jiajia Li · 3 shared papers, 2016–2018 · strength 0.20
  20. Yutong Chen · 1 shared paper, 2024 · strength 0.18
  21. Ting Li · 1 shared paper, 2021 · strength 0.12
  22. Jian Li · 1 shared paper, 2018 · strength 0.07
  23. Hong Su · 1 shared paper, 2018 · strength 0.07
  24. Jiajia Li · 1 shared paper, 2017 · strength 0.06
  25. Shaojing Chen · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.